|
Name |
Cyclo(L-Tyr-L-Pro-L-Phe-trans-4-hydroxy-L-Pro)
|
| Molecular Formula | C28H32N4O6 | |
| IUPAC Name* |
(3S,6S,8R,12S,15S)-3-benzyl-8-hydroxy-12-[(4-hydroxyphenyl)methyl]-1,4,10,13-tetrazatricyclo[13.3.0.06,10]octadecane-2,5,11,14-tetrone
|
|
| SMILES |
C1C[C@H]2C(=O)N[C@H](C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@H](C(=O)N2C1)CC4=CC=CC=C4)O)CC5=CC=C(C=C5)O
|
|
| InChI |
InChI=1S/C28H32N4O6/c33-19-10-8-18(9-11-19)14-22-28(38)32-16-20(34)15-24(32)26(36)30-21(13-17-5-2-1-3-6-17)27(37)31-12-4-7-23(31)25(35)29-22/h1-3,5-6,8-11,20-24,33-34H,4,7,12-16H2,(H,29,35)(H,30,36)/t20-,21+,22+,23+,24+/m1/s1
|
|
| InChIKey |
ZGIGRYSYJMUJMP-DFWAIWNTSA-N
|
|
| Synonyms |
Cyclo(L-Tyr-L-Pro-L-Phe-trans-4-hydroxy-L-Pro)
|
|
| CAS | NA | |
| PubChem CID | 139583586 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 520.6 | ALogp: | 1.4 |
| HBD: | 4 | HBA: | 6 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 139.0 | Aromatic Rings: | 5 |
| Heavy Atoms: | 38 | QED Weighted: | 0.464 |
| Caco-2 Permeability: | -6.269 | MDCK Permeability: | 0.00000521 |
| Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.095 |
| Human Intestinal Absorption (HIA): | 0.845 | 20% Bioavailability (F20%): | 0.999 |
| 30% Bioavailability (F30%): | 0.999 |
| Blood-Brain-Barrier Penetration (BBB): | 0.033 | Plasma Protein Binding (PPB): | 63.98% |
| Volume Distribution (VD): | 0.299 | Fu: | 40.18% |
| CYP1A2-inhibitor: | 0.004 | CYP1A2-substrate: | 0.042 |
| CYP2C19-inhibitor: | 0.181 | CYP2C19-substrate: | 0.075 |
| CYP2C9-inhibitor: | 0.534 | CYP2C9-substrate: | 0.872 |
| CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.238 |
| CYP3A4-inhibitor: | 0.819 | CYP3A4-substrate: | 0.202 |
| Clearance (CL): | 3.885 | Half-life (T1/2): | 0.735 |
| hERG Blockers: | 0.121 | Human Hepatotoxicity (H-HT): | 0.98 |
| Drug-inuced Liver Injury (DILI): | 0.529 | AMES Toxicity: | 0.01 |
| Rat Oral Acute Toxicity: | 0.933 | Maximum Recommended Daily Dose: | 0.911 |
| Skin Sensitization: | 0.121 | Carcinogencity: | 0.054 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.025 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004971 | ![]() |
0.558 | D0J7XL | ![]() |
0.358 | ||
| ENC002149 | ![]() |
0.554 | D0E2OU | ![]() |
0.355 | ||
| ENC003593 | ![]() |
0.504 | D09PZZ | ![]() |
0.354 | ||
| ENC005092 | ![]() |
0.500 | D0V3ZA | ![]() |
0.351 | ||
| ENC002030 | ![]() |
0.500 | D0U7SH | ![]() |
0.349 | ||
| ENC005408 | ![]() |
0.500 | D0SP3D | ![]() |
0.346 | ||
| ENC000867 | ![]() |
0.500 | D0N4OW | ![]() |
0.346 | ||
| ENC005847 | ![]() |
0.500 | D01TSI | ![]() |
0.343 | ||
| ENC005206 | ![]() |
0.500 | D0I0DL | ![]() |
0.341 | ||
| ENC005484 | ![]() |
0.481 | D09NNH | ![]() |
0.341 | ||